X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ALEMBIC PHARMA with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALEMBIC PHARMA   MYLAN
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
MYLAN
Dec-14
ALEMBIC PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7924,055-   
Low Rs4432,858-   
Sales per share (Unadj.) Rs167.01,388.2-  
Earnings per share (Unadj.) Rs38.2167.2-  
Cash flow per share (Unadj.) Rs42.0269.2-  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs84.9690.1-  
Shares outstanding (eoy) m188.52378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.72.5 148.5%   
Avg P/E ratio x16.220.7 78.3%  
P/CF ratio (eoy) x14.712.8 114.5%  
Price / Book Value ratio x7.35.0 145.2%  
Dividend payout %10.50-   
Avg Mkt Cap Rs m116,3831,307,810 8.9%   
No. of employees `000NA25.0 0.0%   
Total wages/salary Rs m4,2140-   
Avg. sales/employee Rs ThNM21,010.8-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,531.1-  
INCOME DATA
Net Sales Rs m31,487525,269 6.0%  
Other income Rs m55-3,062 -1.8%   
Total revenues Rs m31,542522,207 6.0%   
Gross profit Rs m10,060130,637 7.7%  
Depreciation Rs m72238,579 1.9%   
Interest Rs m3722,657 0.2%   
Profit before tax Rs m9,35666,339 14.1%   
Minority Interest Rs m0-272 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1602,790 77.4%   
Profit after tax Rs m7,19463,277 11.4%  
Gross profit margin %31.924.9 128.5%  
Effective tax rate %23.14.2 549.1%   
Net profit margin %22.812.0 189.7%  
BALANCE SHEET DATA
Current assets Rs m15,066461,781 3.3%   
Current liabilities Rs m7,674361,020 2.1%   
Net working cap to sales %23.519.2 122.4%  
Current ratio x2.01.3 153.5%  
Inventory Days Days6778 85.8%  
Debtors Days Days41107 37.9%  
Net fixed assets Rs m8,237121,519 6.8%   
Share capital Rs m37718,575 2.0%   
"Free" reserves Rs m15,4160-   
Net worth Rs m16,005261,110 6.1%   
Long term debt Rs m0390,073 0.0%   
Total assets Rs m24,5941,051,728 2.3%  
Interest coverage x255.23.9 6,498.1%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x1.30.5 256.3%   
Return on assets %29.48.2 359.8%  
Return on equity %44.924.2 185.5%  
Return on capital %58.713.6 430.6%  
Exports to sales %55.70-   
Imports to sales %10.40-   
Net fx Rs m12,4930-   
CASH FLOW
From Operations Rs m9,30469,047 13.5%  
From Investments Rs m-3,105-54,452 5.7%  
From Financial Activity Rs m-1,959-18,194 10.8%  
Net Cashflow Rs m4,240-3,599 -117.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.04 Rs / USD

Compare ALEMBIC PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ALEMBIC PHARMA With: PANACEA BIOTECH  J.B.CHEMICALS  MERCK LTD  NATCO PHARMA  STERLING BIOTECH  



Today's Market

Sensex Trades Rangebound; Metal, Pharma Stocks Top Losers(12:30 pm)

After opening the day flat share markets in India are trading on a dull note and are presently trading below the dotted line.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jun 18, 2018 03:17 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - UNICHEM LAB COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS